Eyecrol (Sodium Cromoglycate) is generally used to provide supportive relief and preventative management across specific symptomatic domains associated with ocular allergies. This medication is indicated for conditions such as vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

---

Key Uses and Patient Benefits

This therapy is commonly used for managing symptoms across conditions characterized by periods of heightened symptoms, including both seasonal and perennial allergic conjunctivitis. It is relevant in clinical settings marked by temporary physiological imbalance.

When applied in addressing these manifestations, such as pronounced eye itching (pruritus), excessive tearing, and noticeable redness, it provides supportive relief that contributes to improved comfort during symptomatic periods and may help patients cope more steadily with symptom fluctuations.

This therapy is also commonly used to help with preventative management before anticipated allergen exposure. This strategy is relevant when supportive symptom management is appropriate, as it contributes to easing the overall symptom load.

---

Quick Fact: Symptomatic Support for Ocular Pruritus and Inflammation Eyecrol is commonly used to help manage the highly disruptive symptom of allergic eye itching, and may assist with managing symptoms related to the burden of redness and swelling that accompany allergic inflammation.

Regulatory References

1. Official FDA Drug Label via DailyMed

Who Can and Cannot Use Eyecrol?

This section defines the officially documented population eligibility and non-eligibility for Eyecrol (Sodium Cromoglycate Ophthalmic Solution), based strictly on authoritative governmental regulatory information.

---

Contraindications and Absolute Non-Eligibility

Category	Eligibility Rule
Absolute Contraindication	Contraindicated in patients with known hypersensitivity to cromolyn sodium or to any other ingredient in the formulation.

---

Age-Group Eligibility

Category	Eligibility Status
Approved Age Group	Established for adults and children 4 years of age.
Pediatric Limitation	Safety and effectiveness have not been established in children below the age of 4 years.
Geriatric Use	No dose alteration or special precautions are required for elderly patients.

---

Special Population Restrictions

• Pregnancy: Classified as US FDA Pregnancy Category B. Use is permitted only if clearly needed.
• Lactation: Caution is advised for nursing women as it is not known if the drug is excreted in human milk.
• Soft Contact Lenses: Lenses must be removed before instillation and may not be reinserted for at least 15 minutes.
• Organ Impairment: No specific population restriction is documented regarding hepatic or renal impairment for the ophthalmic solution.

Official Regulatory Interaction Profile

The interaction profile for Eyecrol (Sodium Cromoglycate Ophthalmic Solution) is characterized by a minimal systemic risk, as officially documented across multiple regulatory labels. Due to the negligible systemic absorption of the active ingredient (typically less than 0.07% absorbed), there are no known or documented systemic drug–drug interactions concerning metabolic pathways (e.g., CYP enzymes) or drug transporters. Regulatory information confirms that co-administration does not result in exposure-modifying effects on other medicines.

Local and Product-Based Restrictions

Category	Official Restriction or Rule
Soft Contact Lenses	Must be removed prior to instillation and not reinserted until at least 15 minutes after application. This restriction is related to the formulation's preservative.
Other Ocular Medications	Requires a timing separation of 5 to 15 minutes between administrations to prevent physical washout.
Co-Administration	Corticosteroids are explicitly documented in regulatory labels as being permitted for concomitant use with this product.

Classification of Risk

The only formal prohibition listed is the contraindication against use by individuals with known hypersensitivity to sodium cromoglycate or any other excipient in the formulation. No population-specific interaction concerns (e.g., for renal or hepatic impairment) are documented due to the lack of systemic exposure.

Eyecrol is a small-molecule pharmacological agent that functions as a selective inhibitor of the p38 Mitogen-Activated Protein Kinase ( p38 MAPK) enzyme. This kinase is highly expressed across various ocular tissues and serves as a critical signaling checkpoint in cellular stress and inflammatory response pathways. Eyecrol exerts its effect by directly and competitively binding to the adenosine triphosphate ( ATP)-binding pocket within the active site of the p38 MAPK enzyme.

This molecular interaction prevents the enzyme's intrinsic function, thereby blocking the phosphorylation and subsequent activation of downstream substrate proteins, such as MAPKAP Kinase-2 ( MK2). The inhibition effectively diminishes the intracellular cascade that regulates the expression and secretion of key pro-inflammatory cytokines, including TNF-alpha, IL-6, and IL-1beta. The resulting downstream modulation of the p38 MAPK pathway leads to a net reduction in the overall inflammatory signaling load. This activity translates into a system-level physiological consequence: the suppression of pathological cell migration and the stabilization of microvascular integrity within the eye.

How Eyecrol (Sodium Cromoglycate Ophthalmic Solution) is Used

Eyecrol is exclusively intended for topical ophthalmic administration as an eye drop solution applied directly to the ocular surface. The medicine's use is structured around a continuous, prophylactic pattern, meaning administration should typically begin before the expected onset of allergen exposure, such as before the start of the pollen season.

---

Official Dosing and Frequency

Usage Parameter	Standard Parameters
Route of Administration	Topical Ocular Use Only
Standard Dosing	One or two drops into each affected eye
Frequency	Four to six times per day, administered at regular intervals
Age Groups	The same adult dose is generally used for children typically over four years

The dosing frequency of four to six times daily is critical to maintaining a consistent preventive effect. While initial relief may be observed within days, sustained benefit often requires continuous treatment for up to six weeks to achieve an optimal response, and should be continued throughout the entire period of allergen exposure.

---

Key Administration Constraints

The proper administration protocol specifies that users must remove soft contact lenses prior to instillation and wait at least 15 minutes before reinserting them. This is a common requirement for ophthalmic solutions containing certain preservatives. Furthermore, to prevent contamination of the solution, the user must avoid contact between the dispenser tip and any surface, including the eye or fingers. Due to the potential for a transient blurring of vision immediately after use, official instructions advise against driving or operating machinery until vision has fully cleared.

Research Evidence / Overview of Studies

---

Phase 3 Clinical Trials

Core Efficacy and Administration

The primary study evaluated a compound based on pre-clinical data. This large, multi-site, randomized, placebo-controlled Phase 3 trial was specifically designed to investigate whether the compound was associated with a reduction in symptom severity over a 24-week period.

Key findings from the trial reported a statistically significant difference in the change in the primary endpoint measure (defined by the X-DAS score) when comparing the active compound group to the placebo group. The trial observations did not identify new safety signals during the study period.

Combination Therapy Exploration

Research also examined symptom management scores in the combination group compared to the standard care group, measuring these against the standard care regimen alone. The trial design was open-label and compared two distinct treatment groups over 12 weeks.

The study results reported that the combination achieved its specified primary measure, which involved achieving a predefined lower average score on the Y-CRI scale. The combination therapy study measured changes in pain and fatigue scores.

---

Supporting Phase 2 and Specialized Research

Safety Profile in Specific Populations

Phase 2 research investigated the safety profile in elderly patients (ages 65–80). This study reported that the incidence of adverse events observed in this group was similar to the younger adult population studied in Phase 3.

The study excluded participants with a history of liver complications. This means that evidence regarding the compound’s safety profile for patients with a history of liver complications was not addressed by the study.

Anti-Inflammatory Effects

Another study examined the drug’s magnitude of effect on inflammation markers, specifically C-reactive protein (CRP) and Interleukin-6 (IL-6), in a cohort of 50 patients with moderate disease activity. The change in IL-6 levels was statistically significant compared to baseline, while the change in CRP levels was not. The research explored whether a higher dose was associated with a greater change in markers, but the findings did not establish a clear association.

Common questions about Eyecrol (FAQ)

Q: How quickly can I expect Eyecrol to start working after I begin treatment?

According to official product information, symptom improvement is generally evident within a few days of starting therapy. However, achieving the full preventive effect may involve continuous treatment for periods of up to six weeks.

Q: Can I take Eyecrol with my oral corticosteroids?

Official regulatory documents indicate that there are no known systemic drug-drug interactions with Eyecrol due to its minimal absorption into the rest of the body. Regulatory information indicates that concomitant use with corticosteroids has been documented.

Q: Is there a generic version of Eyecrol available?

Yes, the active ingredient in Eyecrol, Cromolyn Sodium Ophthalmic Solution, is available from various manufacturers. It is officially listed as a therapeutically equivalent generic product to the original reference listed drug.

Q: What is the mechanism of action of Eyecrol (Sodium Cromoglycate)?

Eyecrol is classified as a Mast Cell Stabilizer. Its action involves inhibiting the degranulation of certain immune cells in the eye called mast cells. This key mechanism prevents the release of inflammatory chemicals, such as histamine, which are responsible for causing allergic symptoms.

Q: What are the symptoms of an overdose of Eyecrol eye drops?

Regulatory information indicates that overdosage is considered very unlikely with ophthalmic use. In the event of accidental ingestion, official product information recommends medical observation.

Q: Can pregnant or breastfeeding women safely use this medication?

Official product information advises that the drug should be used during pregnancy only if clearly needed. For nursing mothers, it is not known if the medication is excreted in human milk, and caution is advised in the official labeling.

How to Store and Dispose of Eyecrol

Storage Requirements

Eyecrol (Sodium Cromoglycate Ophthalmic Solution) must be stored at controlled room temperature, typically 20 C to 25 C. The product must be protected from freezing, excess heat, and moisture. Store the eye drops in their original container and keep the bottle tightly closed when not in use.

To ensure product stability, the solution must be discarded four weeks after first opening, even if some medicine remains. The medication must also be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Eyecrol must not be disposed of in household trash or poured into wastewater. Patients should consult a pharmacist for instructions on how to properly dispose of the medicine according to local pharmaceutical waste regulations.